These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30471270)

  • 21. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy.
    Emsellem HA; Thorpy MJ; Lammers GJ; Shapiro CM; Mayer G; Plazzi G; Chen D; Carter LP; Villa KF; Lee L; Menno D; Black J; Dauvilliers Y
    Sleep Med; 2020 Mar; 67():128-136. PubMed ID: 31926465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Solriamfetol for the Management of Excessive Daytime Sleepiness.
    Cuomo MC; Sheehan AH; Jordan JK
    J Pharm Pract; 2022 Dec; 35(6):963-970. PubMed ID: 33882756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between the Epworth Sleepiness Scale and the Maintenance of Wakefulness Test in Obstructive Sleep Apnea Patients Treated with Positive Airway Pressure.
    Basille D; Baud ME; Andrejak C; Basille-Fantinato A; Jounieaux V
    Respir Med Res; 2020 Nov; 78():100787. PubMed ID: 32920453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea.
    Vinckenbosch F; Asin J; de Vries N; Vonk PE; Donjacour CEHM; Lammers GJ; Overeem S; Janssen H; Wang G; Chen D; Carter LP; Zhou K; Vermeeren A; Ramaekers JG
    Hum Psychopharmacol; 2022 Nov; 37(6):e2845. PubMed ID: 35633275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solriamfetol: A Review in Excessive Daytime Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnoea.
    Hoy SM
    CNS Drugs; 2023 Nov; 37(11):1009-1020. PubMed ID: 37847434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP: A Randomized Trial.
    Pépin JL; Georgiev O; Tiholov R; Attali V; Verbraecken J; Buyse B; Partinen M; Fietze I; Belev G; Dokic D; Tamisier R; Lévy P; Lecomte I; Lecomte JM; Schwartz JC; Dauvilliers Y;
    Chest; 2021 Apr; 159(4):1598-1609. PubMed ID: 33121980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea.
    Powell J; Piszczatoski C; Garland S
    Ann Pharmacother; 2020 Oct; 54(10):1016-1020. PubMed ID: 32270686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study.
    Herring WJ; Liu K; Hutzelmann J; Snavely D; Snyder E; Ceesay P; Lines C; Michelson D; Roth T
    Sleep Med; 2013 Oct; 14(10):955-63. PubMed ID: 23920422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial.
    Weaver TE; Drake CL; Benes H; Stern T; Maynard J; Thein SG; Andry JM; Hudson JD; Chen D; Carter LP; Bron M; Lee L; Black J; Bogan RK
    Ann Am Thorac Soc; 2020 Aug; 17(8):998-1007. PubMed ID: 32353246
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluating pharmacological treatments for excessive daytime sleepiness in obstructive sleep apnea: A comprehensive network meta-analysis and systematic review.
    Neshat SS; Heidari A; Henriquez-Beltran M; Patel K; Colaco B; Arunthari V; Lee Mateus AY; Cheung J; Labarca G
    Sleep Med Rev; 2024 Aug; 76():101934. PubMed ID: 38754208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial.
    Dauvilliers Y; Verbraecken J; Partinen M; Hedner J; Saaresranta T; Georgiev O; Tiholov R; Lecomte I; Tamisier R; Lévy P; Scart-Gres C; Lecomte JM; Schwartz JC; Pépin JL;
    Am J Respir Crit Care Med; 2020 May; 201(9):1135-1145. PubMed ID: 31917607
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea.
    Carley DW; Prasad B; Reid KJ; Malkani R; Attarian H; Abbott SM; Vern B; Xie H; Yuan C; Zee PC
    Sleep; 2018 Jan; 41(1):. PubMed ID: 29121334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Findings of the Maintenance of Wakefulness Test and its relationship with response to modafinil therapy for residual excessive daytime sleepiness in obstructive sleep apnea patients adequately treated with nasal continuous positive airway pressure.
    Inoue Y; Miki M; Tabata T
    Sleep Med; 2016; 27-28():45-48. PubMed ID: 27938918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study.
    Schwartz JR; Hirshkowitz M; Erman MK; Schmidt-Nowara W
    Chest; 2003 Dec; 124(6):2192-9. PubMed ID: 14665500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying clinically important difference on the Epworth Sleepiness Scale: results from a narcolepsy clinical trial of JZP-110.
    Scrima L; Emsellem HA; Becker PM; Ruoff C; Lankford A; Bream G; Khayrallah M; Lu Y; Black J
    Sleep Med; 2017 Oct; 38():108-112. PubMed ID: 29031743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysis.
    Pépin JL; Lehert P; Ben Messaoud R; Joyeux-Faure M; Caussé C; Asin J; Barbé F; Bonsignore MR; Randerath W; Verbraecken J; Craig S; Dauvilliers Y
    EClinicalMedicine; 2024 Oct; 76():102843. PubMed ID: 39346006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Solriamfetol Titration and AdministRaTion (START) in Patients with Obstructive Sleep Apnea: A Retrospective Chart Review and Hypothetical Patient Scenario.
    Singh H; Hyman D; Parks GS; Chen A; Foley C; Baldys B; Ito D; Thorpy MJ
    Adv Ther; 2022 Sep; 39(9):4359-4373. PubMed ID: 35927541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression.
    Krystal AD; Harsh JR; Yang R; Rippon GA; Lankford DA
    J Clin Psychiatry; 2010 Jan; 71(1):32-40. PubMed ID: 20051221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea.
    Abad VC; Guilleminault C
    Expert Rev Respir Med; 2018 Dec; 12(12):1007-1019. PubMed ID: 30365900
    [No Abstract]   [Full Text] [Related]  

  • 40. Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy.
    Thorpy MJ; Hyman D; Parks GS; Chen A; Foley C; Baldys B; Ito D; Singh H
    Clin Ther; 2022 Oct; 44(10):1356-1369. PubMed ID: 36171171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.